Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GRAIL, Inc. (Nasdaq: GRAL) files reports with the U.S. Securities and Exchange Commission that provide detail on its operations as a healthcare diagnostics company focused on multi-cancer early detection. On this page, you can review GRAIL’s SEC filings, including current reports on Form 8-K that describe material events such as private placements, equity distribution agreements, commercial leases, preliminary financial results, and strategic collaboration arrangements.
Recent 8-K filings outline securities purchase agreements for private placements of common stock and pre-funded warrants, a stock purchase agreement with Samsung-related entities tied to a planned business collaboration for commercialization of the Galleri test in Asia, and an equity distribution agreement that allows at-the-market offerings of common stock through designated sales agents. Other filings describe a long-term lease for a new corporate headquarters in Sunnyvale, California and the release of quarterly financial results, along with the company’s use of non-GAAP measures such as Adjusted Gross Profit (Loss) and Adjusted EBITDA.
Through these filings, investors can see how GRAIL structures its financings, the key terms of its strategic agreements, and selected information about its financial condition and operations. Stock Titan’s platform adds AI-powered summaries that explain the main points of each filing in plain language, highlight important sections, and help distinguish between one-time transactions and ongoing obligations. Users can also quickly locate information related to equity issuances, registration rights, and other matters that may affect existing or prospective shareholders.